Searchable abstracts of presentations at key conferences in endocrinology

ea0099oc5.5 | Oral Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

B-RAF and MEK inhibitor argeted therapy in papillary craniopharyngiomas: results from the French national multicenter study

De Alcubierre Dario , Gkasdaris Grigorios , Briet Claire , Almairac Fabien , Boetto Julien , Mouly Celine , Larrieu-Ciron Delphine , Joncour Anthony , Mordrel Margaux , Vasiljevic Alexandre , Villa Chiara , Sergeant Camille , Ducray Francois , Feuvret Loic , Baussart Bertrand , Raverot Gerald , Jouanneau Emmanuel

Background: Papillary craniopharyngiomas (PCPs) are driven by V600E BRAF mutations in 95% of cases. Recently, combined anti-BRAF/MEK targeted therapy (TT) has emerged as a potential treatment in aggressive PCPs. However, standardized data on large cohorts are still lacking. Our study aimed to assess the real-life efficacy and safety of TT in patients with PCPs.Methods: This was a retrospective national multicenter study involving patients with V600E BRAF...